{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:00Z","timestamp":1792783320673,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Basel","id":[{"id":"https:\/\/ror.org\/02s6k3f65","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brain tumors are the most common solid cancers occurring in children, with pediatric low-grade gliomas (pLGG) being the most frequent central nervous system (CNS) tumors in children. The overall survival of pLGG is excellent, with a ten-year survival of 85%\u201396%. Prognostic factors include age, gender, anatomical location, and histological and molecular subtype. Despite the excellent survival rates, children suffering from pLGG often have a diminished quality of life due to functional or neurologic deficits either caused by the primary tumor or as a side effect of their treatment. In this study, we describe the epidemiology of pLGG in Switzerland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The target population comprised children aged 0\u201317 years, diagnosed with histologically verified pLGG during 1990\u20132019 while residing in Switzerland. We retrieved the data from the Swiss Childhood Cancer Registry (ChCR). We calculated crude incidence rates per 100,000 person-years and observed survival (OS) using the Kaplan-Meier estimator (non-parametric univariable analysis). We estimated OS separately according to age histological subgroup and treatment group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 591 pLGG during 1990\u20132019 in Switzerland. Most pLGG were diagnosed at the age of 2\u201311 years (\n                      <jats:italic>n<\/jats:italic>\n                      = 352, 59.6%). Around half of pLGG were supratentorial located (\n                      <jats:italic>n<\/jats:italic>\n                      = 286, 48.4%), while the other half (\n                      <jats:italic>n<\/jats:italic>\n                      = 266, 45.0%) occurred infratentorial. Most pLGG (82.0%) were World Health Organization (WHO) grade 1. The vast majority of pLGG (\n                      <jats:italic>n<\/jats:italic>\n                      = 501, 84.8%) were treated with surgery, either alone (\n                      <jats:italic>n<\/jats:italic>\n                      = 441, 74.6%) or in combination with other treatments. The lowest 5- and 10-year survival was observed in children who received surgery followed by radiotherapy and\/or chemotherapy (40% and 20%). Astrocytoma excluding pilocytic astrocytoma had a significantly lower 5-year,\u00a010-year and total survival (98.8%, 85.8%, and 82.1%) compared to the other histopathological subtypes (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.024).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first report on the incidence and survival of children with pLGG in Switzerland. Children with pLGG have an excellent long-term survival rate of over 90%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12519-026-01085-8","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:41:19Z","timestamp":1789202479000},"page":"1083-1094","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and survival of pediatric low-grade gliomas in Switzerland"],"prefix":"10.1007","volume":"22","author":[{"given":"Ladina","family":"Greuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Michalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelagh","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas V.","family":"der Weid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Licci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Wyss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehuda","family":"Soleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"1085_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/AHMT.S53391","volume":"8","author":"TP Diwanji","year":"2017","unstructured":"Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther. 2017;8:99\u2013113. https:\/\/doi.org\/10.2147\/AHMT.S53391.","journal-title":"Adolesc Health Med Ther"},{"key":"1085_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2011","unstructured":"Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015. Neuro Oncol. 2011;20:iv1\u201386. https:\/\/doi.org\/10.1093\/neuonc\/noy131.","journal-title":"Neuro Oncol"},{"key":"1085_CR3","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/s1470-2045(20)30064-4","volume":"21","author":"J Fangusaro","year":"2020","unstructured":"Fangusaro J, Witt O, Hern\u00e1iz Driever P, Bag AK, de Blank P, Kadom N, et al. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020;21:e305\u201316. https:\/\/doi.org\/10.1016\/s1470-2045(20)30064-4.","journal-title":"Lancet Oncol"},{"key":"1085_CR4","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00381-015-2781-8","volume":"31","author":"CT Lin","year":"2015","unstructured":"Lin CT, Riva-Cambrin JK. Management of posterior fossa tumors and hydrocephalus in children: a review. Childs Nerv Syst. 2015;31:1781\u20139. https:\/\/doi.org\/10.1007\/s00381-015-2781-8.","journal-title":"Childs Nerv Syst"},{"key":"1085_CR5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/pbc.24958","volume":"61","author":"P Bandopadhayay","year":"2014","unstructured":"Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ, et al. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014;61:1173\u20139. https:\/\/doi.org\/10.1002\/pbc.24958.","journal-title":"Pediatr Blood Cancer"},{"key":"1085_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/neuonc\/nos202","volume":"14","author":"AK Gnekow","year":"1996","unstructured":"Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 1996;14:1265\u201384. https:\/\/doi.org\/10.1093\/neuonc\/nos202.","journal-title":"Neuro Oncol"},{"key":"1085_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20:1011\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(19)30277-3.","journal-title":"Lancet Oncol"},{"key":"1085_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11060-020-03592-8","volume":"149","author":"N Manoharan","year":"2020","unstructured":"Manoharan N, Choi J, Chordas C, Zimmerman MA, Scully J, Clymer J, et al. Trametinib for the treatment of recurrent\/progressive pediatric low-grade glioma. J Neurooncol. 2020;149:253\u201362. https:\/\/doi.org\/10.1007\/s11060-020-03592-8.","journal-title":"J Neurooncol"},{"key":"1085_CR9","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/neuonc\/noae074","volume":"26","author":"P O\u2019Hare","year":"2024","unstructured":"O\u2019Hare P, Cooney T, de Blank P, Gutmann DH, Kieran M, Milde T, et al. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: a modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition. Neuro Oncol. 2024;26:1357\u201366. https:\/\/doi.org\/10.1093\/neuonc\/noae074.","journal-title":"Neuro Oncol"},{"key":"1085_CR10","doi-asserted-by":"publisher","first-page":"100169","DOI":"10.1016\/j.ejcped.2024.100169","volume":"4","author":"K Roka","year":"2024","unstructured":"Roka K, Scheinemann K, Avula S, Maduro JH, Thomale UW, Sehested A, et al. European standard clinical practice recommendations for primary pediatric low-grade gliomas. EJC Paediatr Oncol. 2024;4:100169. https:\/\/doi.org\/10.1016\/j.ejcped.2024.100169.","journal-title":"EJC Paediatr Oncol"},{"key":"1085_CR11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/neuonc\/noaa031","volume":"22","author":"S Acharya","year":"2020","unstructured":"Acharya S, Liu JF, Tatevossian RG, Chiang J, Qaddoumi I, Gajjar A, et al. Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis. Neuro Oncol. 2020;22:1203\u201313. https:\/\/doi.org\/10.1093\/neuonc\/noaa031.","journal-title":"Neuro Oncol"},{"key":"1085_CR12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/children8111075","volume":"8","author":"L Greuter","year":"2021","unstructured":"Greuter L, Guzman R, Soleman J. Pediatric and adult low-grade gliomas: where do the differences lie? Children (Basel). 2021;8:1075. https:\/\/doi.org\/10.3390\/children8111075.","journal-title":"Children (Basel)"},{"key":"1085_CR13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/cncr.29907","volume":"122","author":"R Krishnatry","year":"2016","unstructured":"Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I, et al. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer. 2016;122:1261\u20139. https:\/\/doi.org\/10.1002\/cncr.29907.","journal-title":"Cancer"},{"key":"1085_CR14","doi-asserted-by":"publisher","first-page":"101942","DOI":"10.1016\/j.canep.2021.101942","volume":"72","author":"MJ Hossain","year":"2021","unstructured":"Hossain MJ, Xiao W, Tayeb M, Khan S. Epidemiology and prognostic factors of pediatric brain tumor survival in the US: evidence from four decades of population data. Cancer Epidemiol. 2021;72:101942. https:\/\/doi.org\/10.1016\/j.canep.2021.101942.","journal-title":"Cancer Epidemiol"},{"key":"1085_CR15","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/jnci\/djp148","volume":"101","author":"GT Armstrong","year":"2009","unstructured":"Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101:946\u201358. https:\/\/doi.org\/10.1093\/jnci\/djp148.","journal-title":"J Natl Cancer Inst"},{"key":"1085_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/pbc.21129","volume":"50","author":"G Michel","year":"2008","unstructured":"Michel G, von der Weid NX, Zwahlen M, Redmond S, Strippoli MF, Kuehni CE. Incidence of childhood cancer in Switzerland: the Swiss childhood cancer registry. Pediatr Blood Cancer. 2008;50:46\u201351. https:\/\/doi.org\/10.1002\/pbc.21129.","journal-title":"Pediatr Blood Cancer"},{"key":"1085_CR17","doi-asserted-by":"publisher","first-page":"1079597","DOI":"10.3389\/fonc.2023.1079597","volume":"13","author":"J Cao","year":"2023","unstructured":"Cao J, Yan W, Zhan Z, Hong X, Yan H. Epidemiology and risk stratification of low-grade gliomas in the United States, 2004-2019: a competing-risk regression model for survival analysis. Front Oncol. 2023;13:1079597. https:\/\/doi.org\/10.3389\/fonc.2023.1079597.","journal-title":"Front Oncol"},{"key":"1085_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/a-1471-5897","volume":"233","author":"AK Gnekow","year":"2021","unstructured":"Gnekow AK, Kandels D, Pietsch T, Bison B, Warmuth-Metz M, Thomale UW, et al. Doubling recruitment of pediatric low-grade glioma within two decades does not change outcome\u2013report from the German LGG studies. Klin Padiatr. 2021;233:107\u201322. https:\/\/doi.org\/10.1055\/a-1471-5897.","journal-title":"Klin Padiatr"},{"key":"1085_CR19","doi-asserted-by":"publisher","first-page":"w14225","DOI":"10.4414\/smw.2015.14225","volume":"145","author":"M Schindler","year":"2015","unstructured":"Schindler M, Mitter V, Bergstraesser E, Gumy-Pause F, Michel G, Kuehni CE, et al. Death certificate notifications in the Swiss Childhood Cancer Registry: assessing completeness and registration procedures. Swiss Med Wkly. 2015;145:w14225. https:\/\/doi.org\/10.4414\/smw.2015.14225.","journal-title":"Swiss Med Wkly"},{"key":"1085_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ijc.30434","volume":"140","author":"M Schindler","year":"1976","unstructured":"Schindler M, Belle FN, Grotzer MA, von der Weid NX, Kuehni CE, Swiss Paediatric Oncology Group SPOG. Childhood cancer survival in Switzerland (1976-2013): time-trends and predictors. Int J Cancer. 1976;140:62\u201374. https:\/\/doi.org\/10.1002\/ijc.30434.","journal-title":"Int J Cancer"},{"key":"1085_CR21","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/cncr.20910","volume":"103","author":"E Steliarova-Foucher","year":"2005","unstructured":"Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005;103:1457\u201367. https:\/\/doi.org\/10.1002\/cncr.20910.","journal-title":"Cancer"},{"key":"1085_CR22","unstructured":"Abawi K, Feller A, Lorez M, Michalopoulou E, Roy E, Spycher B, Weitkunat R. Childhood Cancer Registry. https:\/\/www.cancer.bfs.admin.ch, https:\/\/www.nacr.ch, and https:\/\/www.childhoodcancerregistry.ch. Accessed 24 Nov 2025."},{"key":"1085_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0895-4356(97)00280-1","volume":"50","author":"H Brenner","year":"1997","unstructured":"Brenner H, Gefeller O. Deriving more up-todate estimates of long-term patient survival. J Clin Epidemiol. 1997;50:211\u20136. https:\/\/doi.org\/10.1016\/s0895-4356(97)00280-1.","journal-title":"J Clin Epidemiol"},{"key":"1085_CR24","unstructured":"R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/. Accessed 24 Nov 2025."},{"key":"1085_CR25","unstructured":"Therneau T. A Package for Survival Analysis in R_. R package version 3.7-0. https:\/\/CRAN.R-project.org\/package=survival. Accessed 24 Nov 2025."},{"key":"1085_CR26","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.7150\/jca.33463","volume":"10","author":"AM Goebel","year":"2019","unstructured":"Goebel AM, Gnekow AK, Kandels D, Witt O, Schmidt R, Hern\u00e1izDriever P. Natural history of pediatric low-grade glioma disease\u2014first multi-state model analysis. J Cancer. 2019;10:6314\u201326. https:\/\/doi.org\/10.7150\/jca.33463.","journal-title":"J Cancer"},{"key":"1085_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/neuonc\/noq178","volume":"13","author":"GT Armstrong","year":"2011","unstructured":"Armstrong GT, Conklin HM, Huang S, Srivastava D, Sanford R, Ellison DW, et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol. 2011;13:223\u201334. https:\/\/doi.org\/10.1093\/neuonc\/noq178.","journal-title":"Neuro Oncol"},{"key":"1085_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/MPH.0b013e3182678bf8","volume":"35","author":"RS Youland","year":"2013","unstructured":"Youland RS, Khwaja SS, Schomas DA, Keating GF, Wetjen NM, Laack NN. Prognostic factors and survival patterns in pediatric low-grade gliomas over 4 decades. J Pediatr Hematol Oncol. 2013;35:197\u2013205. https:\/\/doi.org\/10.1097\/MPH.0b013e3182678bf8.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1085_CR29","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s00381-024-06504-7","volume":"40","author":"AS Plant-Fox","year":"2024","unstructured":"Plant-Fox AS, Tabori U. Future perspective of targeted treatments in pediatric low-grade glioma (pLGG): the evolution of standard-of-care and challenges of a new era. Childs Nerv Syst. 2024;40:3291\u20139. https:\/\/doi.org\/10.1007\/s00381-024-06504-7.","journal-title":"Childs Nerv Syst"},{"key":"1085_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3171\/2024.2.peds23236","volume":"34","author":"MM Kameda-Smith","year":"2024","unstructured":"Kameda-Smith MM, Green K, Hutton DL, Jeelani NUO, Thompson DNP, Hargrave D, et al. The role of reoperation in pediatric cerebellar pilocytic astrocytoma. J Neurosurg Pediatr. 2024;34:169\u201375. https:\/\/doi.org\/10.3171\/2024.2.peds23236.","journal-title":"J Neurosurg Pediatr"},{"key":"1085_CR31","doi-asserted-by":"publisher","first-page":"e2200199","DOI":"10.1200\/GO.22.00199","volume":"8","author":"R Ward","year":"2022","unstructured":"Ward R, Jones HM, Witt D, Boop F, Bouffet E, Rodriguez-Galindo C, et al. Outcomes of children with low-grade gliomas in low- and middle-income countries: a systematic review. JCO Glob Oncol. 2022;8:e2200199. https:\/\/doi.org\/10.1200\/GO.22.00199.","journal-title":"JCO Glob Oncol"},{"key":"1085_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/neuonc\/noad195","volume":"26","author":"J Fangusaro","year":"2024","unstructured":"Fangusaro J, Jones DT, Packer RJ, Gutmann DH, Milde T, Witt O, et al. Pediatric low-grade glioma: state-of-the-art and ongoing challenges. Neuro Oncol. 2024;26:25\u201337. https:\/\/doi.org\/10.1093\/neuonc\/noad195.","journal-title":"Neuro Oncol"},{"key":"1085_CR33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/neuonc\/noae004","volume":"26","author":"DC Moreira","year":"2024","unstructured":"Moreira DC, Bouffet E, Qaddoumi I. The greatest challenge for pediatric low-grade glioma. Neuro Oncol. 2024;26:975\u20136. https:\/\/doi.org\/10.1093\/neuonc\/noae004.","journal-title":"Neuro Oncol"},{"key":"1085_CR34","unstructured":"WHO Global Initiative for Childhood Cancer: An Overview. https:\/\/www.who.int\/publications\/m\/item\/global-initiative-for-childhood-cancer. Accessed 24 Nov 2025."},{"key":"1085_CR35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(18)30909-4","volume":"20","author":"ZJ Ward","year":"2019","unstructured":"Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Atun R. Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol. 2019;20:483\u201393. https:\/\/doi.org\/10.1016\/S1470-2045(18)30909-4.","journal-title":"Lancet Oncol"},{"key":"1085_CR36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ng.2611","volume":"45","author":"J Zhang","year":"2013","unstructured":"Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45:602\u201312. https:\/\/doi.org\/10.1038\/ng.2611.","journal-title":"Nat Genet"},{"key":"1085_CR37","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","volume":"68","author":"DT Jones","year":"2008","unstructured":"Jones DT, Kocialkowski S, Liu L, Pearson DM, B\u00e4cklund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68:8673\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2097.","journal-title":"Cancer Res"},{"key":"1085_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/neuonc\/nox141","volume":"20","author":"DTW Jones","year":"2018","unstructured":"Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, et al. Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018;20:160\u201373. https:\/\/doi.org\/10.1093\/neuonc\/nox141.","journal-title":"Neuro Oncol"},{"key":"1085_CR39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s40478-020-01054-w","volume":"8","author":"MA Lazow","year":"2020","unstructured":"Lazow MA, Hoffman L, Schafer A, Osorio DS, Bou\u00e9 DR, Rush S, et al. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. Acta Neuropathol Commun. 2020;8:182. https:\/\/doi.org\/10.1186\/s40478-020-01054-w.","journal-title":"Acta Neuropathol Commun"},{"key":"1085_CR40","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s00381-024-06449-x","volume":"40","author":"J Bennett","year":"2024","unstructured":"Bennett J, Yeo KK, Tabori U, Hawkins C, Lim-Fat MJ. Pediatric-type low-grade gliomas in adolescents and young adults-challenges and emerging paradigms. Childs Nerv Syst. 2024;40:3329\u201339. https:\/\/doi.org\/10.1007\/s00381-024-06449-x.","journal-title":"Childs Nerv Syst"},{"key":"1085_CR41","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-025-00962-x","volume":"6","author":"J Bennett","year":"2025","unstructured":"Bennett J, Levine AB, Nobre L, Negm L, Chung J, Fang K, et al. A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesis. Nat Rev Cancer. 2025;6:1102\u201319. https:\/\/doi.org\/10.1038\/s43018-025-00962-x.","journal-title":"Nat Rev Cancer"},{"key":"1085_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-024-04857-2","volume":"171","author":"C Cacciotti","year":"2025","unstructured":"Cacciotti C, Tabori U, Hawkins C, Bennett J. Targeting the RAS\/MAPK pathway in children with glioma. J Neurooncol. 2025;171:265\u201377. https:\/\/doi.org\/10.1007\/s11060-024-04857-2.","journal-title":"J Neurooncol"},{"key":"1085_CR43","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s00381-024-06598-z","volume":"40","author":"J Soleman","year":"2024","unstructured":"Soleman J, Constantini S, Roth J. Incidental brain tumor findings in children: prevalence, natural history, management, controversies, challenges, and dilemmas. Childs Nerv Syst. 2024;40:3179\u201387. https:\/\/doi.org\/10.1007\/s00381-024-06598-z.","journal-title":"Childs Nerv Syst"},{"key":"1085_CR44","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1227\/NEU.0b013e318214a66e","volume":"68","author":"JH Wisoff","year":"2011","unstructured":"Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children\u2019s Oncology Group. Neurosurgery. 2011;68:1548\u201354. https:\/\/doi.org\/10.1227\/NEU.0b013e318214a66e.","journal-title":"Neurosurgery"},{"key":"1085_CR45","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s00381-024-06561-y","volume":"40","author":"KN Lorincz","year":"2024","unstructured":"Lorincz KN, Gorodezki D, Schittenhelm J, Zipfel J, Tellermann J, Tatagiba M, et al. Role of surgery in the treatment of pediatric low-grade glioma with various degrees of brain stem involvement. Childs Nerv Syst. 2024;40:3037\u201350. https:\/\/doi.org\/10.1007\/s00381-024-06561-y.","journal-title":"Childs Nerv Syst"},{"key":"1085_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/a-0889-8256","volume":"231","author":"AK Gnekow","year":"2019","unstructured":"Gnekow AK, Kandels D, Tilburg CV, Azizi AA, Opocher E, Stokland T, et al. SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr. 2019;231:107\u201335. https:\/\/doi.org\/10.1055\/a-0889-8256.","journal-title":"Klin Padiatr"},{"key":"1085_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","volume":"81","author":"AK Gnekow","year":"2017","unstructured":"Gnekow AK, Walker DA, Kandels D, Picton S, Perilongo Giorgio, Grill J, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u2264 16 years) low grade glioma a final report. Eur J Cancer. 2017;81:206\u201325. https:\/\/doi.org\/10.1016\/j.ejca.2017.04.019.","journal-title":"Eur J Cancer"},{"key":"1085_CR48","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.1993.11.5.850","volume":"11","author":"RJ Packer","year":"1993","unstructured":"Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11:850\u20136. https:\/\/doi.org\/10.1200\/JCO.1993.11.5.850.","journal-title":"J Clin Oncol"},{"key":"1085_CR49","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374:1344\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1500925.","journal-title":"N Engl J Med"},{"key":"1085_CR50","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1200\/JCO.19.01270","volume":"37","author":"DS Bitterman","year":"2019","unstructured":"Bitterman DS, MacDonald SM, Yock TI, Tarbell NJ, Wright KD, Chi SN, et al. Revisiting the role of radiation therapy for pediatric low-grade glioma. J Clin Oncol. 2019;37:3335\u20139. https:\/\/doi.org\/10.1200\/JCO.19.01270.","journal-title":"J Clin Oncol"},{"key":"1085_CR51","doi-asserted-by":"publisher","first-page":"e28465","DOI":"10.1002\/pbc.28465","volume":"67","author":"S Tran","year":"2020","unstructured":"Tran S, Lim PS, Bojaxhiu B, Teske C, Baust K, Zepter S, et al. Clinical outcomes and quality of life in children and adolescents with primary brain tumors treated with pencil beam scanning proton therapy. Pediatr Blood Cancer. 2020;67:e28465. https:\/\/doi.org\/10.1002\/pbc.28465.","journal-title":"Pediatr Blood Cancer"},{"key":"1085_CR52","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1038\/s41467-023-40235-8","volume":"14","author":"R Sigaud","year":"2023","unstructured":"Sigaud R, Albert TK, Hess C, Hielscher T, Winkler N, Kocher D, et al. MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas. Nat Commun. 2023;14:4533. https:\/\/doi.org\/10.1038\/s41467-023-40235-8.","journal-title":"Nat Commun"},{"key":"1085_CR53","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garr\u00e8 ML, Hara J, Plant-Fox A, Aerts I, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med. 2023;389:1108\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2303815.","journal-title":"N Engl J Med"},{"key":"1085_CR54","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00381-020-04658-8","volume":"36","author":"J Soleman","year":"2020","unstructured":"Soleman J, Kozyrev DA, Ben-Sira L, Constantini S, Roth J. Management of incidental brain tumors in children: a systematic review. Childs Nerv Syst. 2020;36:1607\u201319. https:\/\/doi.org\/10.1007\/s00381-020-04658-8.","journal-title":"Childs Nerv Syst"},{"key":"1085_CR55","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s00381-018-3836-4","volume":"34","author":"J Roth","year":"2018","unstructured":"Roth J, Soleman J, Paraskevopoulos D, Keating RF, Constantini S. Incidental brain tumors in children: an international neurosurgical, oncological survey. Childs Nerv Syst. 2018;34:1325\u201333. https:\/\/doi.org\/10.1007\/s00381-018-3836-4.","journal-title":"Childs Nerv Syst"},{"key":"1085_CR56","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/neuonc\/noq092","volume":"12","author":"T Stokland","year":"2010","unstructured":"Stokland T, Liu JF, Ironside JW, Ellison DW, Taylor R, Robinson KJ, et al. A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol. 2010;12:1257\u201368. https:\/\/doi.org\/10.1093\/neuonc\/noq092.","journal-title":"Neuro Oncol"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01085-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-026-01085-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01085-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:00:22Z","timestamp":1791669622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-026-01085-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1007\/s12519-026-01085-8","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ChCR has ethical approval for the anonymous analysis of data from its registry. No additional ethical approval was required for this analysis, as per the ChCR guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No generative AI was used in the creation of this article.","order":3,"name":"Ethics","label":"AI usage statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}